Although no changes in the percentage of CD8 T cells were observed by flow cytometry (data not shown), future studies will investigate if the decrease in PD-L1 is accompanied by enhanced activity of CD8, leading to the increase in survival and reduction in metastatic disease observed with INCB05743 treatment (Figure 1). The gene discussed is CD8A; the disease is metastatic neoplasm.